CordenPharma Expands Lipid Supply for Moderna

CordenPharma announced on May 28, 2020 an amendment to an existing manufacturing agreement with Moderna, Inc. that enables CordenPharma to manufacture large-scale volumes of Moderna’s lipid excipients to be used in the manufacture of Moderna’s vaccine candidate (mRNA-1273) against the novel coronavirus (SARS-CoV-2).

The agreement expands a lipids manufacturing agreement originally signed in 2016 between Moderna and CordenPharma Switzerland to include CordenPharma Chenôve (France) and CordenPharma Colorado. The agreement will begin immediately to meet Moderna’s increasing demand to scale manufacturing of their vaccine candidate.

Source: CordenPharma